Preclinical
Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody
Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease
GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal
GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset
Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects
SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages
mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.
Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery
Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism
Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks
Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange